MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.
Taggart, James; Ho, Tzu-Chieh; Amin, Elianna; Xu, Haiming; Barlowe, Trevor S; Perez, Alexendar R; Durham, Benjamin H; Tivnan, Patrick; Okabe, Rachel; Chow, Arthur; Vu, Ly; Park, Sun Mi; Prieto, Camila; Famulare, Christopher; Patel, Minal; Lengner, Christopher J; Verma, Amit; Roboz, Gail; Guzman, Monica; Klimek, Virginia M; Abdel-Wahab, Omar; Leslie, Christina; Nimer, Stephen D; Kharas, Michael G.
; 7: 10739, 2016 Feb 22.
Artigo em Inglês | MEDLINE | ID: mdl-26898884
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation.
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia.
Runx1 downregulates stem cell and megakaryocytic transcription programs that support niche interactions.
How One Thing Led to Another.
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.